Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

PTN Palatin Technologies Inc New

0,9549

0,0049 (0,52%)

Nach Börsenschluss

Zuletzt aktualisiert: 00:44:14

Verzögert um 15 Minuten

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Palatin Technologies Charts.

Palatin Technologies (AMEX:PTN)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Palatin Technologies Charts.

News Palatin Technologies Inc New

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Donnerstag 19 Dezember 2024 (1 Monat vor) • PR Newswire (US)

Form 8-K - Current report
Montag 16 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Montag 16 Dezember 2024 (1 Monat vor) • PR Newswire (US)

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Montag 25 November 2024 (2 Monate vor) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 14 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 14 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Donnerstag 14 November 2024 (2 Monate vor) • PR Newswire (US)

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Freitag 8 November 2024 (3 Monate vor) • PR Newswire (US)

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Montag 4 November 2024 (3 Monate vor) • PR Newswire (US)

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Donnerstag 31 Oktober 2024 (3 Monate vor) • PR Newswire (US)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Mittwoch 30 Oktober 2024 (3 Monate vor) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Mittwoch 30 Oktober 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere Palatin Technologies Inc New News-Artikel

JP Morgan Chase

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen